WEE1 kinase as a target for cancer therapy

Journal of Clinical Oncology

Volumn 33, Issue 30, 2015, Pages 3485-3487

  Mueller, Sabine ^a   Haas Kogan, Daphne A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; DNA; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG; WEE1 KINASE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; CANCER THERAPY; CELL CYCLE CHECKPOINT; DNA DAMAGE; DNA REPAIR; DRUG TARGETING; HUMAN; PRIORITY JOURNAL; FEMALE; MALE; NEOPLASMS;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES;

EID: 84945218784     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.2290     Document Type: Article

References (34)

1. Russell P, Nurse P: Negative regulation of mitosis by wee1 +, a gene encoding a protein kinase homolog. Cell 49:559-567, 1987
2. Mir SE, De Witt Hamer PC, Krawczyk PM, et al: In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 18:244-257, 2010
3. Aarts M, Sharpe R, Garcia-Murillas I, et al: Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov 2:524-539, 2012
4. Kogiso T, Nagahara H, Hashimoto E, et al: Efficient induction of apoptosis by wee1 kinase inhibition in hepatocellular carcinoma cells. PLoS One 9:e100495, 2014
5. Pappano WN, Zhang Q, Tucker LA, et al: Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells. BMC Cancer 14:430 2014
6. Harris PS, Venkataraman S, Alimova I, et al: Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma. Mol Cancer 13:72 2014
7. Hirai H, Iwasawa Y, Okada M, et al: Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 8:2992-3000, 2009
8. Bridges KA, Hirai H, Buser CA, et al: MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res 17: 5638-5648, 2011
9. Petitjean A, Mathe E, Kato S, et al: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622-629, 2007
10. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88:323-331, 1997
11. Kaelin WG Jr: The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5:689-698, 2005
12. Rajeshkumar NV, De Oliveira E, Ottenhof N, et al: MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 17:2799-2806, 2011
13. Mueller S, Hashizume R, Yang X, et al: Targeting Wee1 for the treatment of pediatric highgrade gliomas. Neuro Oncol 16:352-360, 2014
14. 2/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma. Cancer Biol Ther 15:380-388, 2014
15. Kato S, Schwaederle M, Daniels GA, et al: Cyclin-dependent kinase pathway aberrations in diverse malignancies: Clinical and molecular characteristics. Cell Cycle 14:1252-1259, 2015
16. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996
17. Kreahling JM, Gemmer JY, Reed D, et al: MK1775, a selective Wee1 inhibitor, shows singleagent antitumor activity against sarcoma cells. Mol Cancer Ther 11:174-182, 2012
18. Guertin AD, Li J, Liu Y, et al: Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. Mol Cancer Ther 12:1442-1452, 2013
19. Goodarzi AA, Noon AT, Deckbar D, et al: ATM signaling facilitates repair of DNA double-strand breaks associated with heterochromatin. Mol Cell 31:167-177, 2008
20. Morgan MA, Parsels LA, Zhao L, et al: Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 70:4972-4981, 2011
21. Parsels LA, Morgan MA, Tanska DM, et al: Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 8:45-54, 2009
22. Do K, Wilsker D, Ji J, et al: Phase I study of single-agent AZD1775 (MK-1775), a WEE1 kinase inhibitor, in patients with refractory solid tumors. J Clin Oncol 33:3409-3415, 2015
23. Yarden RI, Pardo-Reoyo S, Sgagias M, et al: BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 30:285-289, 2002
24. Li M, Yu X: Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation. Cancer Cell 23:693-704, 2013
25. Karnak D, Engelke CG, Parsels LA, et al: Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Clin Cancer Res 20:5085-5096, 2014
26. Chilà R, Basana A, Lupi M, et al: Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma. Oncotarget 6:3394-3408, 2015
27. Russell MR, Levin K, Rader J, et al: Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. Cancer Res 73:776-784, 2013
28. Carrassa L, Chilà R, Lupi M, et al: Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle 11:2507-2517, 2012
29. Golding SE, Morgan RN, Adams BR, et al: Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol Ther 8:730-738, 2009
30. Dai Y, Yu C, Singh V, et al: Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res 61:5106-5115, 2001
31. Dai Y, Chen S, Pei XY, et al: Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood 112:2439-2449, 2008
32. Tang D, Wu D, Hirao A, et al: ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem 277: 12710-12717, 2002
33. Wu D, Chen B, Parihar K, et al: ERK activity facilitates activation of the S-phase DNA damage checkpoint by modulating ATR function. Oncogene 25:1153-1164, 2006
34. Wei F, Xie Y, Tao L, et al: Both ERK1 and ERK2 kinases promote G2/M arrest in etoposide-treated MCF7 cells by facilitating ATM activation. Cell Signal 22:1783-1789, 2010 doi: 10.1200/JCO.2015.62.2290; published online ahead of print at www.jco.org on July 27, 2015